Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Filings indexed 399 across all filing types
Latest filing 2026-05-05 Interim / Quarterly Rep…
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
10-Q - MUSTANG BIO, INC. (0001680048) (Filer)
Interim / Quarterly Report
2026-05-05 English
8-K - MUSTANG BIO, INC. (0001680048) (Filer)
Regulatory Filings
2026-04-17 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-05 English
Director's Dealing 2026
Director's Dealing
2026-01-05 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-12-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-12-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.